Organoids are becoming an increasingly important factor in the development of personalized medicine, which is based on each patient's personal genetic profile. These microscopically small "reproductions" of human organs are ideally suited for carrying out medical tests. Not only that, but they also stand to help scientists develop a much greater understanding of neurodegenerative diseases and various forms of cancer. The newly launched Gri3DTM platform designed by the Swiss startup SUN bioscience opens up a means of culturing organoids on a large scale and thus harnessing their potential far more extensively.
Sylke Hoehnel, one of the founders of SUN bioscience, explains the process by which Gri3DTM came about: "Our research efforts at the École Polytechnique Fédérale de Lausanne (EPFL) led us to discover a new method for cultivating organoids from stem cells in small, U-shaped microwells in a hydrogel matrix. The cells are self-organizing and grow in the desired 3D structure on this platform." Based on its sound expertise in biotechnology, chemistry and microtechnology, the CSEM then proved to be the ideal partner for standardizing this method of producing organoids. "Besides its outstanding technical skills, the CSEM also demonstrates a very impressive multidisciplinary approach and wealth of experience in developing production processes," explains Nathalie Brandenberg, another of the co-founders of SUN bioscience.
CSEM SA Central Switzerland Center (6055 Alpnach, Switzerland)